How GS-7977+RBV performed in difficult-to-treat group
Success(90s%) or failure(60s%) of this 7977+RBV regimen for GT2/3 is important for the short term longevity of Incivek sales (off-label use for GT1 patients is possible). It is almost certain that they are not seeing the 100% SVR rate for GT2/3 when the treatment time length is 12 or less weeks contrary to their earlier results. If they can show that this most advanced regimen is better in efficacy than 6 mo. Peg/Rbv (80% SVR rate), then the 7977 regimen could reach the market before 2015, and Incivek sales will plummet well before its launch. If the recently released results (in the 60s %) are valid, then the drug can be used only for those patients who cannot tolerate Interferon, and Incivek sales could survive for another year or two until their triple combo (+5885) could become approved in 2016.